Right ventricular contractility affects the clinical efficacy of add-on tolvaptan following hospitalization for heart failure in patients with significant tricuspid regurgitation-Reference-Cited by-同舟云学术

Right ventricular contractility affects the clinical efficacy of add-on tolvaptan following hospitalization for heart failure in patients with significant tricuspid regurgitation

Published:2021-10-22 Issue: Volume: Page:
ISSN:0910-8327
Container-title:Heart and Vessels
language:en
Short-container-title:Heart Vessels

Author:

Hachiya Rumi,Mochizuki Yasuhide^ORCID,Shibakai Mina,Omomo Yui,Kuroki Yui,Endo Yukiko,Ichikawa Saaya,Miyazaki Haruka,Chino Saori,Toyosaki Eiji,Ota Masashi,Fukuoka Hiroto,Shinke Toshiro

Publisher

Springer Science and Business Media LLC

Subject

Cardiology and Cardiovascular Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00380-021-01973-1.pdf

Reference31 articles.

1. Agricola E, Marini C, Stella S, Monello A, Fisicaro A, Tufaro V, Slavich M, Oppizzi M, Castiglioni A, Cappelletti A, Margonato A (2017) Effects of functional tricuspid regurgitation on renal function and long-term prognosis in patients with heart failure. J Cardiovasc Med (Hagerstown) 18(2):60–68

2. Agricola E, Stella S, Gullace M, Ingallina G, D’Amato R, Slavich M, Oppizzi M, Ancona MB, Margonato A (2012) Impact of functional tricuspid regurgitation on heart failure and death in patients with functional mitral regurgitation and left ventricular dysfunction. Eur J Heart Fail 14(8):902–908

3. Benfari G, Antoine C, Miller WL, Thapa P, Topilsky Y, Rossi A, Michelena HI, Pislaru S, Enriquez-Sarano M (2019) Excess mortality associated with functional tricuspid regurgitation complicating heart failure with reduced ejection fraction. Circulation 140(3):196–206

4. Tsutsui H, Isobe M, Ito H, Ito H, Okumura K, Ono M, Kitakaze M, Kinugawa K, Kihara Y, Goto Y, Komuro I, Saiki Y, Saito Y, Sakata Y, Sato N, Sawa Y, Shiose A, Shimizu W, Shimokawa H, Seino Y, Node K, Higo T, Hirayama A, Makaya M, Masuyama T, Murohara T, Momomura SI, Yano M, Yamazaki K, Yamamoto K, Yoshikawa T, Yoshimura M, Akiyama M, Anzai T, Ishihara S, Inomata T, Imamura T, Iwasaki YK, Ohtani T, Onishi K, Kasai T, Kato M, Kawai M, Kinugasa Y, Kinugawa S, Kuratani T, Kobayashi S, Sakata Y, Tanaka A, Toda K, Noda T, Nochioka K, Hatano M, Hidaka T, Fujino T, Makita S, Yamaguchi O, Ikeda U, Kimura T, Kohsaka S, Kosuge M, Yamagishi M, Yamashina A (2019) JCS 2017/JHFS 2017 guideline on diagnosis and treatment of acute and chronic heart failure—digest version. Circ J 83(10):2084–2184

5. Gheorghiade M, Gattis WA, O’Connor CM, Adams KF Jr, Elkayam U, Barbagelata A, Ghali JK, Benza RL, McGrew FA, Klapholz M, Ouyang J, Orlandi C (2004) Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 291(16):1963–1971

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The right ventricle systolic force ratio could predict the severity of the tricuspid regurgitation‐RIVIERA ratio;Journal of Clinical Ultrasound;2023-03-31